InvestorsHub Logo
Followers 163
Posts 12871
Boards Moderated 1
Alias Born 01/26/2016

Re: exwannabe post# 63741

Sunday, 06/05/2016 8:59:12 PM

Sunday, June 05, 2016 8:59:12 PM

Post# of 698656
exwannabe,

Other than a feeling, what makes you skeptical of Direct's effectiveness when the optimized protocol is utilized? Do you understand how engineered T-cells are activated and how that might relate to Direct? Why do you think that Dr. Subbiah said that Direct could be at the forefront of treatment options for 10 years when he first saw it's potential? Why did automation for Direct find a way to jump ahead of automation for L as a NWBO priority? You are not alone in your skepticism. Then again most scientists let alone investors, professional or not, do not have the slightest idea why Direct's Phase 1 results were completely predictable even though better results were hoped for. There was an outside chance that the early part of the regimen would create a response long and strong enough to lead to overcoming immunosupression and create strong immune memory. What they have learned from Phase 1 will allow Phase 2 to create a dramatic difference in results since their hands were tied by "first in man" designation with Phase 1.

The immune system can be made tolerant or it can act very quickly and in some cases too quickly depending on how it is activated and supressed. NWBO knows this and is being careful to get it right and they are using the right cells to regulate response.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News